Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Icosavax, Inc. (ICVX : NSDQ)
 
 • Company Description   
Icosavax Inc. is a biopharmaceutical company which focuses on life-threatening respiratory diseases. The company's virus-like particle platform technology involved in developing vaccines against infectious diseases. Icosavax Inc. is based in SEATTLE.

Number of Employees: 22

 
 • Price / Volume Information   
Yesterday's Closing Price: $21.07 Daily Weekly Monthly
20 Day Moving Average: 127,579 shares
Shares Outstanding: 39.04 (millions)
Market Capitalization: $822.61 (millions)
Beta:
52 Week High: $49.99
52 Week Low: $19.14
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -37.83% -35.89%
12 Week -46.28% -46.81%
Year To Date % %
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1616 EASTLAKE AVE E SUITE 208
-
SEATTLE,WA 98102
USA
ph: 858-775-4523
fax: -
ir@icosavax.com http://icosavax.com
 
 • General Corporate Information   
Officers
Adam Simpson - Chief Executive Officer
Tadataka Yamada - Chairman
Thomas Russo - Chief Financial Officer
Elisha P. Gould - Director
Jason Hafler - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 45114M109
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/21
Next Expected EPS Date: 02/21/22
Share - Related Items
Shares Outstanding: 39.04
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $822.61 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.46 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.55 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 02/21/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.81
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 54.55%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -4.04%
ROE
09/30/21 - -
06/30/21 - -
03/31/21 - -
ROA
09/30/21 - -
06/30/21 - -
03/31/21 - -
Current Ratio
09/30/21 - 36.67
06/30/21 - 18.95
03/31/21 - -
Quick Ratio
09/30/21 - 36.67
06/30/21 - 18.95
03/31/21 - -
Operating Margin
09/30/21 - -
06/30/21 - -
03/31/21 - -
Net Margin
09/30/21 - -
06/30/21 - -
03/31/21 - -
Pre-Tax Margin
09/30/21 - -
06/30/21 - -
03/31/21 - -
Book Value
09/30/21 - 7.49
06/30/21 - -1.05
03/31/21 - -
Inventory Turnover
09/30/21 - -
06/30/21 - -
03/31/21 - -
Debt-to-Equity
09/30/21 - 0.00
06/30/21 - -
03/31/21 - -
Debt-to-Capital
09/30/21 - 0.00
06/30/21 - -
03/31/21 - -
 

Powered by Zacks Investment Research ©